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Summary
Subcutaneous (SQ) vs. intramuscular (IM) vaccination may cause fewer injection site 
complications in children with bleeding disorders, but little is known about comparative 
immunogenicity. To compare immunogenicity of hepatitis B virus (HBV) vaccination 
administered SQ or IM to individuals <2 years old with bleeding disorders, we performed a 
retrospective analysis of HBV surface antibody titres among patients enrolled in the universal data 
collection database who had received three doses of HBV vaccine solely by one route (SQ or IM). 
Data reviewed were from an initial visit before 24 months of age, until time of hepatitis antibody 
titre testing. The SQ and IM study groups did not differ in demographics, haemophilia type or 
severity or bleeding history. The mean age at the time of HBV surface antibody (anti-HBs) testing 
was 56.9 ± 20.3 months. Eighty-five of 92 subjects (92.4%) who received vaccine SQ developed a 
positive antibody titre (>12 IU/L), compared to 101/114 (88.6%) who received IM (P = 0.30). 
There was no statistically significant difference in distribution of titre values. The average age of 
the subjects at time of testing was 53 ± 20 months in the SQ group vs. 60 ± 20 months in the IM 
group (P = 0.02). The average time between the last dose of vaccine and anti-HBs testing was 47.6 
± 18.5 months among SQ vaccinated subjects vs. 51.6 ± 20.5 months in the IM group (P = 0.2). 
Immunogenicity to hepatitis B vaccination by the SQ and IM routes is similar.
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Introduction
Individuals with haemophilia and other bleeding disorders require immunizations 
recommended by the Advisory Committee on Immunization Practices (ACIP) to prevent 
communicable diseases, such as hepatitis B virus (HBV) infection, as good preventive 
practice, and because of potential transmission by factor infusions and blood product 
transfusions [1–3]. HBV vaccines in the US are FDA-licensed for intramuscular (IM) 
administration to achieve optimal protective antibody titres. Hepatitis B vaccines are 
routinely administered IM to infants as a 3-dose series at birth, 2, and 6 months post-
delivery. Hepatitis B vaccine can be administered as a single vaccine or as one portion of a 
combination vaccination [2,4].
Children with bleeding disorders, especially with severe disease, are at risk for muscle 
haematomas with IM injections. Clotting factor concentrates can be administered to 
minimize this risk; however, factor is very expensive and requires intravenous 
administration which can be technically difficult in babies and small children. Thus, there 
has been interest in subcutaneous (SQ) vaccination, but few data exist concerning its safety. 
Moreover, there has been concern that the SQ route may not provide the same level of 
immunogenicity [5,6]. There are few published studies comparing SQ and IM routes for 
HBV vaccination within the bleeding disorder population. Zanetti, et al. found that 98% of 
people with haemophilia immunized SQ developed antibodies to HBV [7]. Based on these 
data, the World Federation of Hemophilia (WFH) has recommended that children with 
haemophilia receive SQ vaccinations [8]. However, in the U.S., the ACIP recommends that 
individuals with bleeding disorders be vaccinated IM unless the patient’s physician feels that 
it is unsafe. In addition, the guidelines specifically state that if the vaccine is given in any 
way other than IM, the dose must be repeated within 1 month [2]. This recommendation is 
supported by the guidelines of the National Hemophilia Foundation’s Medical and Scientific 
Advisory Committee (MASAC) [1]. Therefore, there continues to be disagreement 
regarding the most efficacious and safe way to administer the HBV vaccine in the bleeding 
disorders population.
The Centers for Disease Control and Prevention (CDC) has supported a public health 
surveillance system established in a network of haemophilia Treatment Centres (HTC) 
throughout the U.S. called the universal data collection (UDC) project [9]. In this study, we 
used data collected in the UDC project to compare the rate of seroconversion to HBV 
vaccine in children who had received HBV vaccination SQ to those who had received it IM.
Methods
To test the hypothesis that there is no difference in the proportion of patients with 
haemophilia A or B, von Willebrand Disease, or other bleeding disorders that develop 
protective levels of hepatitis B surface antibodies (anti-HBs) among patients vaccinated for 
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hepatitis B either by the SQ or IM route, we conducted a retrospective study. Data for the 
study were collected during the period July 2003 to September 2011 by medical care 
providers. The project was conducted with approval from the Institutional Review Boards of 
CDC and all participating institutions. Participants (or parents of minor children) gave 
informed consent.
Patients receiving care in HTCs were eligible to participate in UDC at any age. Among 
those enrolled before their second birthday, data were collected using special forms relevant 
to young children including information on vaccinations. A registration form collected data 
on month and year of birth, sex and parent- reported race and ethnicity. For this analysis, 
race and ethnicity were categorized as non-Hispanic white, non-Hispanic black, Hispanic 
(either black or white) or other. Data entered into the UDC by the treating HTC were used to 
determine the type of bleeding disorder and severity. For children with haemophilia, severity 
was based on the factor activity at baseline with values <1%, 1–5% and >5% of normal 
categorized as severe, moderate and mild disease respectively. Clinic records were used to 
determine whether the child had ever had a bleeding episode prior to enrolment in UDC.
Children could participate in UDC as often as every 6 months until they reached age 2 years, 
after which participation was limited to once per year. Prior to age 2 years, data were 
collected on hepatitis B vaccination including the route of administration (SQ or IM) and the 
dates for up to three doses. In addition, data were collected on the number of bleeding 
episodes according to body site including intramuscular haematoma. No blood draws were 
required for children under 2 years of age in UDC.
For UDC participants older than 2 years of age, a blood sample was collected, isolated and 
frozen and sent overnight on cold packs to the CDC serum bank according to a standard 
protocol. Specimens were then tested for serologic evidence of infection or exposure to 
hepatitis B by the CDC coagulation laboratory using the Vitros ECi Immunoassay Analyzer 
(Ortho-Clinical Diagnostics, Raritan, NJ, USA) to perform a chemiluminescent 
immunometric assay that involves the reaction of anti-HBs in the sample with HBsAg 
coated onto wells. According to manufacturer specifications for this assay, a result ≥12.0 
mIU/mL anti-HBs was considered positive and the individual is presumed to be immune to 
HBV infection [10]. All testing was performed according to instructions provided by the 
manufacturer and all results were within manufacturer-supplied quality control guidelines. 
All blood specimens were also tested for hepatitis B core antibody and, when positive, for 
surface antigen.
For the present study, we searched the UDC database for participants with at least one visit 
both before and after 2 years of age and a CDC-reported serologic test result for hepatitis B 
surface antibodies. A positive anti-HBs test in the absence of a positive core antibody test 
was presumed to be indicative of an effective vaccine response to hepatitis B vaccination.
We hypothesized that there would be no difference between the routes of administration in 
the proportion of patients who develop a protective level of anti-HBs immune response, and 
we anticipated that analysis of the main study outcome would result in a failure to reject this 
null hypothesis. There are two reasons that this outcome could occur: either there is truly no 
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difference in immunogenicity between the two routes of administration, or there is a lack of 
adequate power to detect a meaningful difference in rates of immunogenicity even if such a 
difference exists.
To calculate the sample size necessary to detect a clinically meaningful difference in 
immunity if it in fact was present, we determined by consensus of the authors that if one of 
the routes of administration resulted in 15% fewer subjects achieving an antibody response, 
this would represent a clinically meaningful difference in efficacy of the vaccination. The 
average rates of HBV seroprotection after three doses are 85–90% [11]. Based on previous 
studies of immunity after hepatitis B vaccination in haemophilia patients, we expected that 
at least 95% of subjects would seroconvert to a minimum of a protective anti-HBs titre of 12 
mIU/mL after vaccination [7,12–16]. Therefore, we considered that a seroconversion rate of 
<80% would be a less than acceptable level. Thus, based on the normal distribution, we 
determined a sample size of nearly 100 subjects in each group would provide 80% power to 
detect a 15% difference in seroprotection rates, specifically 95% in one group and 80% in 
the other group.
Statistical analysis
All UDC participants with data collected both prior to and after age 2 years, and who had 
received exactly three doses of Hepatitis B vaccine, were categorized as receiving 
vaccination either entirely through the SQ or IM or a combination of routes. Only data 
collected from subjects receiving three vaccination doses recorded as solely by one route 
(either SQ or IM) were used in the analyses. We compared the distributions of demographic 
and clinical characteristics between subjects who had been vaccinated exclusively by the SQ 
or the IM route and between subjects with and without an immune response to immunization 
using chi-squared tests. The proportions of subjects who reported intramuscular haematomas 
at UDC visits prior to age 2 years were also compared using chi-squared tests.
Since none of the studied characteristics was known to be associated with either the 
exposure (vaccination route) or the outcome (immune status), there was no potential for 
confounding by these characteristics. Therefore, we assessed the strength of the association 
between route of administration and immune status using Student’s t-test. We compared 
antibody levels, age at serologic testing and time intervals between vaccination and testing 
by vaccination route, using an analysis of variance. All analyses were performed using SAS 
statistical software (SAS Institute, Cary, NC, USA), and statistical testing with resultant P-
values ≤0.05 were judged statistically significant.
Results
There were a total of 767 subjects who participated in UDC both before and after age 2 
years during the period July 2003–September 2011. Of these, while some information on the 
route of vaccination was available on 436 (56.8%), complete information on all three doses 
of vaccine was available on 256 (33.4%). Two-hundred seven had all three doses by only 
one route. One subject who had a negative surface antibody test but a positive core antibody 
test was excluded leaving 206 subjects who formed the study population. Of these, 92/206 
subjects (44.7%) received all doses by the SQ route and 114/206 subjects (55.3%) received 
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all doses by the IM route. For the SQ route, 69% had all doses by 7 months and 94% by 12 
months. For the IM route, 59% of those subjects had all 3 doses by 7 months and 88.5% by 
12 months.
Characteristics of the study population are shown in Table 1, including bivariate associations 
with route of administration and anti-HBs status. The racial and ethnic distribution of the 
study subjects was similar to that of all UDC participants and most study subjects were 
males, reflecting the predominantly male haemophilia population. Nearly 60% of subjects 
with haemophilia had severe disease and 71% of subjects had a history of a bleeding episode 
at the time of enrolment in UDC. No subjects were HIV infected or otherwise 
immunocompromised.
There was no statistically significant association between race/ethnicity, sex, type of 
bleeding disorder or bleeding history and the route of vaccination administration (Table 1). 
Subjects with mild haemophilia were less likely to receive vaccine by the SQ route. The 
proportions attaining a positive antibody level were uniformly high and no associations with 
patient characteristics reached statistical significance (Table 1).
Among those vaccinated SQ, 92.4% were anti-HBs positive, whereas 88.6% of those with 
IM vaccination were antibody positive (P = 0.3). The mean age at time of hepatitis B titre 
was 56.9 ± 20.3 months and ranged from 8 to 97 months. There was no difference in the 
distribution of titre values between the two groups. The average age of testing was 53 ± 20 
months in the SQ group vs. 60 ± 20 months in the IM group (P = 0.02). The average time 
between the last dose of vaccine and testing for hepatitis B antibodies was 47.6 ± 18.5 
months among subjects vaccinated SQ vs. 51.6 ± 20.5 months among those receiving IM 
vaccination (P = 0.2).
Among the 92 subjects who had received SQ vaccination, 10 (10.9%) children had a total of 
12 intramuscular haematomas recorded in their clinical records. Among the 114 subjects 
receiving IM vaccination, 23 (20.2%) children had a total of 38 intramuscular haematomas. 
The difference between the proportions of children experiencing intramuscular haematomas 
by vaccination route did not reach statistical significance (P = 0.07). Given the nature of the 
data, there was no way to determine if haematoma formation was related to vaccine 
administration.
Discussion
There is discrepancy among recommendations published by international bleeding disorder 
expert panels regarding the route of vaccination in patients with bleeding disorders [1–
3,17,18]. The Association of Hemophilia Clinic Directors of Canada, the United Kingdom 
Haemophilia Centre Doctors’ Organisation and WFH recommend that SQ HBV vaccination 
is preferred for patients with bleeding disorders [3,8,17–19]. In contrast, ACIP and MASAC 
recommendations specifically recommend IM injection of hepatitis B vaccination [1,2]. 
Despite these inconsistencies, of the 767 children who participated in the surveillance, 222 
(29%) had received at least one dose of HBV vaccine SQ and these subjects were distributed 
throughout 52 (58.4%) of the 89 enrolling HTCs. Therefore, more than one-half of the 
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federally supported U.S. HTCs providing care to children with bleeding disorders appear to 
be recommending SQ administration of HBV vaccine. We speculate that the reasons for this 
recommendation are to avoid IM haematoma formation at the site of injection and to 
minimize need for factor in patients not on prophylactic therapy [6].
Ragni, et al. evaluated seroconversion to hepatitis A vaccine in those receiving the 
vaccination SQ. They found SQ injection to be as effective as IM in inducing immunity in 
their population [20]. Zanetti, et al. found that hepatitis B vaccination resulted in the 
development of antibodies to hepatitis B surface antigen in 98% of haemophilia patients 
immunized SQ [7]. Conversely, Fessard, et al. found that antibody response was higher 
when vaccination was given IM [5]. It is possible that early investigation of immunogenicity 
of hepatitis B vaccination by varying routes was influenced by concomitant HIV infection 
and the continued potential for hepatitis infection from factor products [7,11,13,21]. Our 
results show no significant difference in immunogenicity between SQ and IM routes for the 
HBV vaccine. However, the overall seroconversion for this population was lower than 
expected a priori, which was estimated at approximately 95% [7,12–16]. We hypothesize 
that this may be due to a delay in HBV titre ascertainment, which averaged closer to 50 
months after the last dose of immunization in both groups rather than the recommended 1 
month.
The proportion of subjects with local haematoma formation appeared higher in those 
receiving vaccination by the IM route in our study, but this difference did not reach 
statistical significance. It should be noted that no information was available regarding the 
cause of the intramuscular haematoma. It is likely that some of the haematomas that 
occurred were unrelated to vaccination or could be subject to recall bias, as data collection 
in the UDC database relies on parent history. A previous study of IM HBV vaccination of 51 
children with haemophilia resulted in a haematoma rate of 4%, none of which were treated 
with factor infusion [22]. No serious complications from SQ administration were reported in 
any previous studies that examined side effects of this method [12–14,16,20,23]. Several 
studies reported local inflammation at the site of injection in a minority of subjects 
[5,12,13,16,20]. Because our study used surveillance data rather than that from a research 
study designed to address this particular issue, we did not have data regarding specific 
complications arising from vaccination.
There are a number of other limitations to this study. First, the retrospective nature of the 
data collected in UDC likely introduced recall bias into some of the exposures and 
outcomes. This may be especially pertinent regarding vaccination, which often takes place at 
the child’s primary care provider rather than the HTC. A second limitation is that to ensure 
that we could attribute the immune response to either the SQ or IM vaccination route; we 
excluded subjects who received the vaccine through multiple routes, thus limiting our 
sample size. Nonetheless, there was adequate sample size to detect a clinically significant 
difference had it been present. We were also unable to identify the type of hepatitis vaccine 
administered. In addition, dates of occurrence were not collected for all events which 
precluded a better assessment of the relationship between certain exposures and outcomes, 
such as the risk of haematomas or inhibitors in association with vaccination. Specifically, 
UDC data do not include date of inhibitor detection; therefore, we were unable to establish 
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when inhibitors developed relative to vaccination. Finally, we did not have data on the 
frequency of factor product administration prior to IM vaccination solely to avoid a 
haematoma. To the extent that this practice occurs, the SQ route provides an effective 
alternative strategy that may decrease the costs and rates of complications associated with 
vaccination. However, caution should be used when extending these data to other 
vaccinations, as comparison of the rate of immunogenicity between the SQ and IM routes 
has only been performed on a selected few immunizations.
Conclusion
Hepatitis B vaccination given SQ appears to be equally efficacious as IM injection in 
inducing protective immunity in individuals with bleeding disorders. Long-term immunity 
and complications of immunization administration in the bleeding disorder population will 
require prospective evaluation.
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